miR‑613 suppresses migration and invasion in esophageal squamous cell carcinoma via the targeting of G6PD Retraction in /10.3892/etm.2023.12246

Su,Xiangyu; Gao,Chanchan; Feng,Xiaoyao; Jiang,Ming

doi:10.3892/etm.2020.8540

miR‑613 suppresses migration and invasion in esophageal squamous cell carcinoma via the targeting of G6PD

Retraction in: /10.3892/etm.2023.12246

Authors:
- Xiangyu Su
- Chanchan Gao
- Xiaoyao Feng
- Ming Jiang
View Affiliations

Affiliations: Department of Oncology, Zhongda Hospital, The Affiliated Hospital of Southeast University, Nanjing, Jiangsu 210009, P.R. China, Department of Radiation Oncology, General Hospital of Eastern Theater Command, Nanjing, Jiangsu 210002, P.R. China, Department of Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing, Jiangsu 210000, P.R. China
Published online on: February 21, 2020 https://doi.org/10.3892/etm.2020.8540
Pages: 3081-3089
Copyright: © Su et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Esophageal squamous cell carcinoma (ESCC) is a common cancer in China and has a high mortality rate. MicroRNAs (miRs) are a family of post‑transcriptional regulators, which negatively regulate target gene expression. miR‑613 has been revealed to be a diagnostic and prognostic biomarker in ESCC. However, the role of miR‑613 in ESCC remains unclear. In the present study, miR‑613 expression was identified to be reduced in tumor tissues in comparison with corresponding adjacent normal tissues. TargetScan and a dual‑luciferase reporter assay verified glucose‑6‑phosphate dehydrogenase (G6PD) as a direct target of miR‑613. In contrast with miR‑613, G6PD expression was increased in tumor tissues compared with matched healthy tissues. Furthermore, overexpression of miR‑613 inhibited cell migration and invasion of Eca109 cells compared with controls, while G6PD overexpression reversed the inhibition induced by miR‑613, as determined by wound healing and Transwell assays. In addition, miR‑613 overexpression decreased the mRNA and protein expression of G6PD, matrix metalloproteinase (MMP)2 and MMP9, and reduced the phosphorylation of signal transducer and activator of transcription 3 (STAT3) compared with controls, while G6PD reversed the effects of miR‑613. However, miR‑613 and G6PD did not affect the expression of STAT3. In conclusion, the aforementioned results suggest that miR‑613 targets G6PD to suppress ESCC cell migration and invasion through reduced MMP2 and MMP9 expression and inactivation of the STAT3 signaling pathway. Thus, the present study may provide a new molecular foundation for treatment of ESCC.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–386. 2015.PubMed/NCBI View Article : Google Scholar
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015.PubMed/NCBI View Article : Google Scholar
3	Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, et al: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 339:1979–1984. 1998.PubMed/NCBI View Article : Google Scholar
4	Liu YT, Zong D, Jiang XS, Yin L, Wang LJ, Wang TT, Zhu J and He X: miR-32 promotes esophageal squamous cell carcinoma metastasis by targeting CXXC5. J Cell Biochem. 120:6250–6263. 2019.PubMed/NCBI View Article : Google Scholar
5	Wang H, Deng F, Liu Q and Ma Y: Prognostic significance of lymph node metastasis in esophageal squamous cell carcinoma. Pathol Res Pract. 213:842–847. 2017.PubMed/NCBI View Article : Google Scholar
6	Pennathur A, Gibson MK, Jobe BA and Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.PubMed/NCBI View Article : Google Scholar
7	Krol J, Loedige I and Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 11:597–610. 2010.PubMed/NCBI View Article : Google Scholar
8	Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 20:460–469. 2014.PubMed/NCBI View Article : Google Scholar
9	Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.PubMed/NCBI View Article : Google Scholar
10	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006.PubMed/NCBI View Article : Google Scholar
11	Mei LL, Qiu YT, Zhang B and Shi ZZ: MicroRNAs in esophageal squamous cell carcinoma: Potential biomarkers and therapeutic targets. Cancer Biomark. 19:1–9. 2017.PubMed/NCBI View Article : Google Scholar
12	Sang Q, Liu X and Sun D: Role of miR-613 as a tumor suppressor in glioma cells by targeting SOX9. Onco Targets Ther. 11:2429–2438. 2018.PubMed/NCBI View Article : Google Scholar
13	Jiang X, Wu J, Zhang Y, Wang S, Yu X, Li R and Huang X: MiR-613 functions as tumor suppressor in hepatocellular carcinoma by targeting YWHAZ. Gene. 659:168–174. 2018.PubMed/NCBI View Article : Google Scholar
14	Li D, Li DQ, Liu D and Tang XJ: MiR-613 induces cell cycle arrest by targeting CDK4 in non-small cell lung cancer. Cell Oncol (Dordr). 39:139–147. 2016.PubMed/NCBI View Article : Google Scholar
15	Wang J, Yang S, Ge W, Wang Y, Han C and Li M: MiR-613 suppressed the laryngeal squamous cell carcinoma progression through regulating PDK1. J Cell Biochem. 119:5118–5125. 2018.PubMed/NCBI View Article : Google Scholar
16	Guan S, Wang C, Chen X, Liu B, Tan B, Liu F, Wang D, Han L, Wang L, Huang X, et al: MiR-613: A novel diagnostic and prognostic biomarker for patients with esophageal squamous cell carcinoma. Tumour Biol. 37:4383–4391. 2016.PubMed/NCBI View Article : Google Scholar
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
18	Li WT, Wang BL, Yang CS, Lang BC and Lin YZ: MiR-613 promotes cell proliferation and invasion in cervical cancer via targeting PTPN9. Eur Rev Med Pharmacol Sci. 22:4107–4114. 2018.PubMed/NCBI View Article : Google Scholar
19	Yang X, Zhang L, Song X, He W, Zhang D, Lu Q, Wu J, Wu C and Jiang J: MicroRNA-613 promotes colon cancer cell proliferation, invasion and migration by targeting ATOH1. Biochem Biophys Res Commun. 504:827–833. 2018.PubMed/NCBI View Article : Google Scholar
20	Xiong H, Yan T, Zhang W, Shi F, Jiang X, Wang X, Li S, Chen Y, Chen C and Zhu Y: miR-613 inhibits cell migration and invasion by downregulating Daam1 in triple-negative breast cancer. Cell Signal. 44:33–42. 2018.PubMed/NCBI View Article : Google Scholar
21	Luzzatto L, Nannelli C and Notaro R: Glucose-6-phosphate dehydrogenase deficiency. Hematol Oncol Clin North Am. 30:373–393. 2016.PubMed/NCBI View Article : Google Scholar
22	Patra KC and Hay N: The pentose phosphate pathway and cancer. Trends Biochem Sci. 39:347–354. 2014.PubMed/NCBI View Article : Google Scholar
23	Jiang P, Du W and Wu M: Regulation of the pentose phosphate pathway in cancer. Protein Cell. 5:592–602. 2014.PubMed/NCBI View Article : Google Scholar
24	Zhang Q, Yang Z, Han Q, Bai H, Wang Y, Yi X, Yi Z, Yang L, Jiang L, Song X, et al: G6PD promotes renal cell carcinoma proliferation through positive feedback regulation of p-STAT3. Oncotarget. 8:109043–109060. 2017.PubMed/NCBI View Article : Google Scholar
25	Lu M, Lu L, Dong Q, Yu G, Chen J, Qin L, Wang L, Zhu W and Jia H: Elevated G6PD expression contributes to migration and invasion of hepatocellular carcinoma cells by inducing epithelial-mesenchymal transition. Acta Biochim Biophys Sin (Shanghai). 50:370–380. 2018.PubMed/NCBI View Article : Google Scholar
26	Cui J, Pan Y, Wang J, Liu Y, Wang H and Li H: MicroRNA-206 suppresses proliferation and predicts poor prognosis of HR-HPV-positive cervical cancer cells by targeting G6PD. Oncol Lett. 16:5946–5952. 2018.PubMed/NCBI View Article : Google Scholar
27	Hu H, Ding X, Yang Y, Zhang H, Li H, Tong S, An X, Zhong Q, Liu X, Ma L, et al: Changes in glucose-6-phosphate dehydrogenase expression results in altered behavior of HBV-associated liver cancer cells. Am J Physiol Gastrointest Liver Physiol. 307:G611–G622. 2014.PubMed/NCBI View Article : Google Scholar
28	Wang X, Liu H, Zhang X, Li X, Gu H, Zhang H and Fan R: G6PD downregulation triggered growth inhibition and induced apoptosis by regulating STAT3 signaling pathway in esophageal squamous cell carcinoma. Tumour Biol. 37:781–789. 2016.PubMed/NCBI View Article : Google Scholar
29	Visse R and Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res. 92:827–839. 2003.PubMed/NCBI View Article : Google Scholar
30	Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002.PubMed/NCBI View Article : Google Scholar
31	Zhang JF, Wang P, Yan YJ, Li Y, Guan MW, Yu JJ and Wang XD: IL-33 enhances glioma cell migration and invasion by upregulation of MMP2 and MMP9 via the ST2-NF-kB pathway. Oncol Rep. 38:2033–2042. 2017.PubMed/NCBI View Article : Google Scholar
32	Yang F, Yu N, Wang H, Zhang C, Zhang Z, Li Y, Li D, Yan L, Liu H and Xu Z: Downregulated expression of hepatoma-derived growth factor inhibits migration and invasion of prostate cancer cells by suppressing epithelial-mesenchymal transition and MMP2, MMP9. PLoS One. 13(e0190725)2018.PubMed/NCBI View Article : Google Scholar
33	Yu H and Jove R: The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.PubMed/NCBI View Article : Google Scholar
34	Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. Biochim Biophys Acta. 1845:136–154. 2014.PubMed/NCBI View Article : Google Scholar
35	Wake MS and Watson CJ: STAT3 the oncogene-still eluding therapy? FEBS J. 282:2600–2611. 2015.PubMed/NCBI View Article : Google Scholar